These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25332259)

  • 1. Cholesterol cholelithiasis in pregnant women: pathogenesis, prevention and treatment.
    de Bari O; Wang TY; Liu M; Paik CN; Portincasa P; Wang DQ
    Ann Hepatol; 2014; 13(6):728-45. PubMed ID: 25332259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.
    Wang HH; Portincasa P; Mendez-Sanchez N; Uribe M; Wang DQ
    Gastroenterology; 2008 Jun; 134(7):2101-10. PubMed ID: 18442485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.
    Wang HH; Portincasa P; de Bari O; Liu KJ; Garruti G; Neuschwander-Tetri BA; Wang DQ
    Eur J Clin Invest; 2013 Apr; 43(4):413-26. PubMed ID: 23419155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Inhibition of Intestinal Cholesterol Absorption on the Prevention of Cholesterol Gallstone Formation.
    Portincasa P; Wang DQ
    Med Chem; 2017; 13(5):421-429. PubMed ID: 28185534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Estrogen Receptor G Protein-Coupled Receptor 30 Enhances Cholesterol Cholelithogenesis in Female Mice.
    Wang HH; de Bari O; Arnatt CK; Liu M; Portincasa P; Wang DQ
    Hepatology; 2020 Dec; 72(6):2077-2089. PubMed ID: 32112420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezetimibe prevents the formation of oestrogen-induced cholesterol gallstones in mice.
    de Bari O; Wang HH; Portincasa P; Paik CN; Liu M; Wang DQ
    Eur J Clin Invest; 2014 Dec; 44(12):1159-68. PubMed ID: 25303682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.
    Hillebrant CG; Nyberg B; Gustafsson U; Sahlin S; Björkhem I; Rudling M; Einarsson C
    Eur J Clin Invest; 2002 Jul; 32(7):528-34. PubMed ID: 12153554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallstone disease: Microlithiasis and sludge.
    Jüngst C; Kullak-Ublick GA; Jüngst D
    Best Pract Res Clin Gastroenterol; 2006; 20(6):1053-62. PubMed ID: 17127187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering drugs and gallstones: a therapeutic option?
    Lioudaki E; Ganotakis ES; Mikhailidis DP
    Curr Pharm Des; 2011 Nov; 17(33):3622-31. PubMed ID: 22074432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol metabolism and serum and biliary noncholesterol sterols in gallstone patients during simvastatin and ursodeoxycholic acid treatments.
    Miettinen TE; Kiviluoto T; Taavitsainen M; Vuoristo M; Miettinen TA
    Hepatology; 1998 Mar; 27(3):649-55. PubMed ID: 9500689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy.
    Saraswat VA; Sharma BC; Agarwal DK; Kumar R; Negi TS; Tandon RK
    J Gastroenterol Hepatol; 2004 Oct; 19(10):1206-11. PubMed ID: 15377301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones.
    Jüngst D; Brenner G; Pratschke E; Paumgartner G
    J Hepatol; 1989 Jan; 8(1):1-6. PubMed ID: 2921499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicinal treatments of cholesterol gallstones: old, current and new perspectives.
    Portincasa P; Di Ciaula A; Wang HH; Moschetta A; Wang DQ
    Curr Med Chem; 2009; 16(12):1531-42. PubMed ID: 19355905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholelithiasis and cholecystitis.
    Schirmer BD; Winters KL; Edlich RF
    J Long Term Eff Med Implants; 2005; 15(3):329-38. PubMed ID: 16022643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones.
    Jüngst C; Sreejayan N; Zündt B; Müller I; Spelsberg FW; Hüttl TP; Kullak-Ublick GA; del Pozo R; Jüngst D; von Ritter C
    Eur J Clin Invest; 2008 Sep; 38(9):634-9. PubMed ID: 18837739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy and the biliary tract.
    Gilat T; Konikoff F
    Can J Gastroenterol; 2000 Nov; 14 Suppl D():55D-59D. PubMed ID: 11110613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-3 polyunsaturated fatty acid attenuates cholesterol gallstones by suppressing mucin production with a high cholesterol diet in mice.
    Kim JK; Cho SM; Kang SH; Kim E; Yi H; Yun ES; Lee DG; Cho HJ; Paik YH; Choi YK; Haam SJ; Shin HC; Lee DK
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1745-51. PubMed ID: 22849613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention.
    Di Ciaula A; Wang DQ; Portincasa P
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):157-171. PubMed ID: 30791781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe prevents cholesterol gallstone formation in mice.
    Zúñiga S; Molina H; Azocar L; Amigo L; Nervi F; Pimentel F; Jarufe N; Arrese M; Lammert F; Miquel JF
    Liver Int; 2008 Aug; 28(7):935-47. PubMed ID: 18783541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans.
    Lanzarotto F; Panarotto B; Sorbara R; Panteghini M; Pagani F; Sosta S; Lanzini A
    Gut; 1999 Apr; 44(4):552-6. PubMed ID: 10075964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.